OncLive TV

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

Percy Lee, MD, discusses different radiation modalities for patients with NSCLC, the increasing complexity of reirradiation, and the strategic use of SABR.

Xiuning Le, MD, PhD, discusses findings from the phase 1/2 SOHO-01 trial evaluating sevabertinib monotherapy in HER2-mutant advanced NSCLC.

Pasi A. Jänne, MD, PhD, discusses OS outcomes with osimertinib with or without chemotherapy based on baseline prognostic factors in EGFR-mutant NSCLC.

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

Sara A. Hurvitz, MD, FACP, shares 5-year efficacy updates from the phase 3 NATALEE trial in HR-positive HER2-negative breast cancer.

Erica L. Mayer, MD, MPH, discusses primary efficacy outcomes for giredestrant in the phase 3 evERA trial in ER-positive, HER2-negative advanced breast cancer.

Kim Nguyen Chi, MD, FRCPC, discusses correlative analyses of prognostic subgroups in the phase 2 PR21 study in PSMA-positive mCRPC.

Srikala Sridhar, MD, MSc, FRCPC, discusses efficacy findings from the ALPACA study and the necessity of improved patient selection for checkpoint inhibitors in PSCC

Andrea Necchi, MD, discusses the role of minimal residual disease assessment in the phase 2 SunRISe-4 trial evaluating TAR-200 plus cetrelimab in MIBC.

Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.

Randy F. Sweis, MD, discusses potential toxicities and mitigation strategies associated with the bispecific T-cell engager XmAb819.

Kevin Elias, MD, discusses the role of olaparib maintenance therapy for patients with BRCA1 and BRCA2-mutated ovarian cancer.

Armeen Mahvash, MD, discusses the clinical impact of the FDA approval of SIR-Spheres Y-90 resin microspheres for unresectable hepatocellular carcinoma.

Vishal A. Patel, MD, discusses the FDA approval of adjuvant cemiplimab for CSCC at high risk of recurrence following surgery and radiation.

Pule Wang, MD, discusses CNS bridging radiotherapy prior to CAR T-cell therapy in B-cell lymphomas.

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.

Solange Peters, MD, PhD, discusses the necessity of global consensus meetings to navigate clinical "gray zones" in lung cancer management.

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Corinne Faivre-Finn, MD, discusses ongoing clinical debates regarding patient selection and optimal delivery of concurrent chemoradiotherapy followed by immunotherapy in LS-SCLC.

Shilpa Gupta, MD, discusses the clinical effects of findings from the phase 3 EV-302/KEYNOTE-A39 trial in locally advanced/metastatic urothelial carcinoma.

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Emil Lou, MD, PhD, FACP, discusses the rationale for evaluating CISH knockout TILs using CRISPR-Cas9 gene editing in metastatic GI cancers.

[The baseline patient population] represents what we see in the real world, with a median age of 73. [This] is older than what we see in [many] clinical trials.